Quincy Attobrah

Lung cancer treatment has changed rapidly since 2021, with new targeted drugs, immunotherapy and treatments designed to overcome resistance.

The FDA granted final approval to OMCAZIO, a new cabozantinib capsule formulation for certain patients with kidney, liver and neuroendocrine cancers.

Prostate cancer treatment has advanced rapidly in five years. Explore key FDA approvals, improved treatments and what these changes mean for patients.

FDA grants accelerated approval to Hyrnuo (sevabertinib) for certain patients with HER2-mutated, advanced or metastatic non-small cell lung cancer.

Bristol Myers Squibb reports positive results from a phase 2 trial of investigational CAR T-cell therapy arlo-cel in relapsed multiple myeloma.

AI is changing breast cancer screening, helping doctors detect cancer and predict future risk. Learn what AI mammography means for patients.

FDA grants accelerated approval to camizestrant for certain advanced breast cancers with ESR1 mutations, offering a new treatment option.

Former NFL linebacker Chris Draft honors his late wife Keasha by advocating for lung cancer research and equitable access to care.

Brynn Forlizzi was just 15 when diagnosed with ovarian cancer. She shares 10 things that helped her navigate treatment while staying connected to her teenage life.

Lung cancer patient and her father, a cancer survivor and caregiver, share how community, hope and self-advocacy helped them through treatment.

Karyopharm submitted an FDA application seeking accelerated approval for XPOVIO plus ruxolitinib for patients with myelofibrosis.

FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this rare blood cancer.

FDA approves Mimrylo (rusfertide) for adults with polycythemia vera, offering a new treatment approach that may reduce the need for frequent blood draws.

FDA approves Rasonque, a first-in-class targeted therapy for metastatic pancreatic cancer, offering a new treatment option for eligible patients.

Dolly Parton has died at 80 following a brief battle with cancer. Learn what is known about her diagnosis, legacy and resources for those affected.

FDA approves Ziihera combinations for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma, expanding treatment options.

Lung cancer advocate Katie shares how losing her father to the disease and her own cancer journey inspire her work with LiveLung today.

Diagnosed with stage 1 lung cancer at 40, Gillian Ryan shares the overwhelming guilt she felt about bringing cancer into her family’s life.

Diagnosed with limited-stage small-cell lung cancer, Tammy shares how treatment progress and a mindset shift helped her find hope.

The FDA approved Pluvicto with hormone therapy for PSMA-positive metastatic prostate cancer, helping delay disease progression in patients.

Heather Prather shares her stage 4 non small cell lung cancer journey, finding hope, joy and support through the LiveLung community and cancer advocacy.

The FDA approved Revtorpyk with fulvestrant, with or without Ibrance, for certain patients with advanced HR-positive, HER2-negative breast cancer.

The FDA approved Keytruda plus Padcev before and after bladder surgery for adults with muscle-invasive bladder cancer, expanding treatment options.

The FDA approved Sarclisa Escena, a new subcutaneous treatment option for adults with multiple myeloma across newly diagnosed and relapsed settings.

Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect at each step.

EPKINLY Plus REVLIMID Improves Progression-Free Survival in Relapsed Diffuse Large B-Cell Lymphoma

FDA approves Tregzi, a new cell therapy that helps reduce chronic graft-versus-host disease after donor stem cell transplant in adults with blood cancers.

FDA approves Trodelvy alone or with Keytruda for the first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer.

Susan Yaguda, oncology nurse at Atrium Health Levine Cancer Institute, transforms cancer care by treating the whole person — mind, body, and spirit — one patient at a time.

FDA approves Ibrance with trastuzumab and endocrine therapy for maintenance treatment of HR-positive, HER2-positive metastatic breast cancer.